A Multicenter, Open-label, Safety and Tolerability Extension Trial of 5 mg and 10 mg Elobixibat Daily in the Treatment of Chronic Idiopathic Constipation
Phase of Trial: Phase III
Latest Information Update: 11 May 2016
At a glance
- Drugs Elobixibat (Primary)
- Indications Constipation
- Focus Adverse reactions
- Acronyms Echo-3
- Sponsors Ferring Pharmaceuticals
- 20 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 28 Aug 2014 Planned End Date changed from 1 Nov 2015 to 1 May 2015 as reported by ClinicalTrials.gov.
- 28 Aug 2014 Planned primary completion date changed from 1 Oct 2015 to 1 May 2015 as reported by ClinicalTrials.gov.